Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30702001 | 1.00 | ADORA2A (0.34) | ADORA2AADORA2BCYP1A2BTK | |
| SCHEMBL10200881 | 0.79 | ADORA2A (0.36) | ADORA2AADORA2BCYP1A2BTK | |
| SCHEMBL7703073 | 0.76 | ADORA2A (0.34) | ADORA2AADORA2BCYP1A2BTK | |
| SCHEMBL6830412 | 0.72 | PDPK1 (0.43) | CYP1A2 | |
| SCHEMBL17875703 | 0.72 | PDPK1 (0.36) | ADORA2AADORA2BCYP1A2 | |
| SCHEMBL19780200 | 0.72 | MAP2K1 (0.37) | ADORA2AADORA2B | |
| SCHEMBL31509722 | 0.72 | — | — | |
| SCHEMBL25112226 | 0.71 | HCAR2 (0.34) | ADORA2AADORA2BCYP1A2 | |
| SCHEMBL28616720 | 0.69 | AMY1A (0.36) | ADORA2AADORA2BCYP1A2 | |
| SCHEMBL24373241 | 0.68 | CYP1A2 (0.35) | ADORA2AADORA2BCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12410183-B2 | Sars-cov2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| EP-4565574-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2025-06-11 | — | — | EP | disclosed |
| CN-116648248-B | Aromatic compound, pharmaceutical composition containing same and application thereof | 成都茵创园医药科技有限公司 | 2025-04-15 | — | — | CN | disclosed |
| US-20250042915-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2025-02-06 | — | — | US | disclosed |
| US-12091420-B2 | SARS-COV2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240116946-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2024-04-11 | — | — | US | disclosed |
| WO-2024031089-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2024-02-08 | — | — | WO | disclosed |
| CN-116648248-A | Aromatic compound, pharmaceutical composition containing same and application thereof | 成都茵创园医药科技有限公司 | 2023-08-25 | — | — | CN | disclosed |
| WO-2022161414-A1 | AROMATIC COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND APPLICATION THEREOF | 成都茵创园医药科技有限公司 | 2022-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042915-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | ADORA2A 4464/4885ADORA2B 4603/4885CYP1A2 152/4885 |
| US-12091420-B2 | SARS-COV2 main protease inhibitors | ACE2, TMPRSS2, ACE | ADORA2A 4464/4885ADORA2B 4603/4885CYP1A2 152/4885 |
| US-20240116946-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | ADORA2A 4464/4885ADORA2B 4603/4885CYP1A2 152/4885 |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | ACE2, TMPRSS2, ACE | ADORA2A 4464/4885ADORA2B 4603/4885CYP1A2 152/4885 |
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | ADORA2A 4464/4885ADORA2B 4603/4885CYP1A2 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.